Eloxx Pharmaceuticals trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Robert E. Ward. Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.
Previous Intraday Performance:
The ELOX shares had a previous change of 0.27% which opened at 11.09 and closed at 11.26. It moved to an intraday high of 11.50 and a low of 10.82.
Over the last five trading days, ELOX shares returned 9.32% and in the past 30 trading days it returned -12.58%. Over three months, it changed 6.13%. In one year it has changed 5.23% and within that year its 52-week high was 24.60 and its 52-week low was 9.12. ELOX stock is 23.46% above its 52 Week Low.
Our calculations result in a 200 day moving average of 13.78 and a 50 day moving average of 11.98. Right now, ELOX stock is trading -18.26% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $404.7m with 35.9m shares outstanding and a float of 16.5m shares. Trading volume was 10,697 shares and has experienced an average volume of 28,409 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Eloxx Pharmaceuticals was -1.45 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.37.
The next earnings report will be: 05-15-2019
EPS growth is an important number as it indicates the future prospects of Eloxx Pharmaceuticals.
Indicators Also to Watch:
Based on the latest filings, there is 58.10% of insider ownership and 30.30% of institutional ownership.
I calculated the beta to be 1.66
Business Wire: Enterprise Financial Reports First Quarter 2019 Results
Based on last reported financials, the company’s return on equity is -146.83%, return on assets is -124.99% and price-to-book is 9.41.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result